Aktienanalyse zu Dianthus Therapeutics Inc (DNTH)DNTHDianthus Therapeutics Inc

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dianthus Therapeutics Inc is currently priced at $82.37, which is significantly below the average analyst price target of $139.80 (calculated from targets of $135, $156, $128, and $158). However, the stock shows a very low RSI of 9.857, indicating it is oversold, which could suggest a potential rebound. The company has a high forward P/E ratio of 0, indicating no expected earnings growth in the near term, and a significant risk is its current net income loss of -$50,215,000 for Q2 2026. Given these factors, while there is potential for upside based on analyst targets, the current financial performance and technical indicators suggest holding rather than buying.